Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Viviane P Muniz"'
Autor:
Sara M Reed, Jussara Hagen, Viviane P Muniz, Timothy R Rosean, Nick Borcherding, Sebastian Sciegienka, J Adam Goeken, Paul W Naumann, Weizhou Zhang, Van S Tompkins, Siegfried Janz, David K Meyerholz, Dawn E Quelle
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e112126 (2014)
Nuclear Interactor of ARF and Mdm2 (NIAM, gene designation Tbrg1) is a largely unstudied inhibitor of cell proliferation that helps maintain chromosomal stability. It is a novel activator of the ARF-Mdm2-Tip60-p53 tumor suppressor pathway as well as
Externí odkaz:
https://doaj.org/article/9c544ff0f4564561a32fe2479115b285
Autor:
Xuefeng Zhang, Jussara Hagen, Viviane P Muniz, Tarik Smith, Gary S Coombs, Christine M Eischen, Duncan I Mackie, David L Roman, Richard Van Rheeden, Benjamin Darbro, Van S Tompkins, Dawn E Quelle
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80228 (2013)
RABL6A (RAB-like 6 isoform A) is a novel protein that was originally identified based on its association with the Alternative Reading Frame (ARF) tumor suppressor. ARF acts through multiple p53-dependent and p53-independent pathways to prevent cancer
Externí odkaz:
https://doaj.org/article/6ed6ebb6df1d4336b6c9a48c9578d33f
Autor:
Chandra K. Maharjan, Shaikamjad Umesalma, Courtney A. Kaemmer, Viviane P. Muniz, Casey Bauchle, Sarah L. Mott, K. D. Zamba, Patrick Breheny, Mariah R. Leidinger, Benjamin W. Darbro, Samuel B. Stephens, David K. Meyerholz, Dawn E. Quelle
Publikováno v:
Biomedicines, Vol 9, Iss 6, p 633 (2021)
Pancreatic neuroendocrine tumors (pNETs) are difficult-to-treat neoplasms whose incidence is rising. Greater understanding of pNET pathogenesis is needed to identify new biomarkers and targets for improved therapy. RABL6A, a novel oncogenic GTPase, i
Externí odkaz:
https://doaj.org/article/0be6e6f7c96143f89dfeb782deeff057
Autor:
Dawn E. Quelle, Benjamin W. Darbro, James R. Howe, Andrew M. Bellizzi, Thomas M. O'Dorisio, Scott K. Sherman, Ryan W. Askeland, Heather J. Major, Aloysius J. Klingelhutz, Francoise A. Gourronc, Frederick W. Quelle, Agshin F. Taghiyev, Sara M. Reed, Kelly C. Falls, Viviane P. Muniz, Jussara Hagen
Figure S2. Representative IPA mechanistic network for signaling regulators predicted to contribute to the RABL6A knockdown phenotype.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fb316efa37fe042ca5e2c480aebbbc9
https://doi.org/10.1158/0008-5472.22404263.v1
https://doi.org/10.1158/0008-5472.22404263.v1
Autor:
Dawn E. Quelle, Benjamin W. Darbro, James R. Howe, Andrew M. Bellizzi, Thomas M. O'Dorisio, Scott K. Sherman, Ryan W. Askeland, Heather J. Major, Aloysius J. Klingelhutz, Francoise A. Gourronc, Frederick W. Quelle, Agshin F. Taghiyev, Sara M. Reed, Kelly C. Falls, Viviane P. Muniz, Jussara Hagen
Table S1. List of differentially regulated genes caused by RABL6A knockdown (KD), relative to control (CON), in BON-1 PNET cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b710410caa0071f21f915ebf926f36c
https://doi.org/10.1158/0008-5472.22404248.v1
https://doi.org/10.1158/0008-5472.22404248.v1
Autor:
Shaikamjad Umesalma, Chandra K. Maharjan, Kokou D. Zamba, Sarah L. Mott, Samuel B. Stephens, Courtney A. Kaemmer, Mariah R. Leidinger, David K. Meyerholz, Patrick Breheny, Viviane P. Muniz, Casey J. Bauchle, Dawn E. Quelle, Benjamin W. Darbro
Publikováno v:
Biomedicines
Volume 9
Issue 6
Biomedicines, Vol 9, Iss 633, p 633 (2021)
Volume 9
Issue 6
Biomedicines, Vol 9, Iss 633, p 633 (2021)
Pancreatic neuroendocrine tumors (pNETs) are difficult-to-treat neoplasms whose incidence is rising. Greater understanding of pNET pathogenesis is needed to identify new biomarkers and targets for improved therapy. RABL6A, a novel oncogenic GTPase, i
Autor:
Viviane P. Muniz, Courtney A. Kaemmer, Sarah L. Mott, Casey J. Bauchle, Kokou D. Zamba, Patrick Breheny, Chandra K. Maharjan, Dawn E. Quelle, Samuel B. Stephens, Mariah R. Leidinger, Benjamin W. Darbro, David K. Meyerholz
Pancreatic neuroendocrine tumors (pNETs) are difficult-to-treat neoplasms whose incidence is rising. Greater understanding of pNET pathogenesis is needed to identify new biomarkers and targets for improved therapy. RABL6A, a novel oncogenic GTPase, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f58ced669b77adc8f0b93f33117b86
https://doi.org/10.1101/2021.03.17.435790
https://doi.org/10.1101/2021.03.17.435790
Autor:
Mariz Vainzof, Lydia U Yamamoto, Patrícia M Kossugue, Luciana LQ Fogaça, Fernando Z Velloso, Danielle Ayub, Viviane P Muniz, Mayana Zatz, Helga CA Silva, Silvia MG Massironi, Maria Angélica Miglino, Carlos Eduardo Ambrosio, Ligia G Miyazato, Julieta RE Moraes, Fernando HF D’Angeles, Joaquim C Lacerda Neto, Ana Carolina Mortari, Alexandre S Borges, Luiz Antonio L Rezende, Sheila C Rahal
Publikováno v:
Revista Neurociências. 13:18-20
Publikováno v:
Revista Neurociências. 13:65-67
Autor:
L.U. Yamamoto, Mariz Vainzof, Dinorah Zilbersztajn-Gotlieb, Juliana Gurgel-Giannetti, Mayana Zatz, Rita de Cássia M. Pavanello, Viviane P. Muniz, Adriano Souza Senkevics, Acary Souza Bulle Oliveira
Publikováno v:
Muscle & Nerve. 45:279-283
We describe a large Brazilian consanguineous kindred with 3 clinically affected patients with a Thomsen myo- tonia phenotype. They carry a novel homozygous nonsense mutation in the CLCN1 gene (K248X). None of the 6 heterozy- gote carriers show any si